Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于2024年度提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度评估报告" which translates to "Half-Year Assessment Report" for the 2024 action plan of the company. It contains detailed operational, financial, and strategic information for the first half of 2024, including revenue, profit figures, product development progress, governance improvements, and investor relations activities. The presence of actual financial data (e.g., revenue and profit numbers) and substantive analysis indicates this is a comprehensive interim report rather than a brief announcement or a certification. The document length (4654 characters) is sufficient to contain detailed content, and it is not merely an announcement of a report publication. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
长春百克生物科技股份公司2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, core technology and R&D progress, and other comprehensive information typical of a half-year financial report. The report period is specified as January 1, 2024 to June 30, 2024, confirming it is an interim period report. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
长春百克生物科技股份公司第五届监事会第二十次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 5th Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes approval of the 2024 semi-annual report and related fundraising usage reports. The text states that the full semi-annual report and related documents are disclosed on the Shanghai Stock Exchange website, indicating this document is an announcement of the meeting decisions and approvals rather than the report itself. The document length is short (1530 characters) and it references other filings for the full reports. Therefore, this is not the semi-annual report itself (which would be an Interim/Quarterly Report - IR), but an announcement of the meeting resolutions and approvals related to the report and fundraising usage. This fits best with the category of Regulatory Filings (RNS), which is the fallback for announcements and compliance disclosures that do not contain the full report or detailed financial data.
2024-08-15 Chinese
长春百克生物科技股份公司关于归还前次用于临时补充流动资金的募集资金暨使用部分闲置募集资金临时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Changchun Baike Biotechnology Co., Ltd. regarding the return of previously used temporary supplementary funds from raised capital and the plan to use part of idle raised funds to temporarily supplement working capital. It includes details about the raised funds, their usage, approvals from the board and supervisory committee, and compliance with regulatory requirements. The document is about the use and management of raised funds, not a full financial report or audit. It is a regulatory announcement related to capital usage and compliance, typical of a Capital/Financing Update. The document length is 4108 characters, which is relatively short but contains substantive information about capital usage rather than just a notice of report publication. Therefore, it fits best under Capital/Financing Update (CAP).
2024-08-15 Chinese
长春百克生物科技股份公司2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report on the official website. The document length is 2647 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. It is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
长春百克生物科技股份公司2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by Changchun Baike Biotechnology Co., Ltd. for the first half of 2024. It includes specifics on the amount of funds raised, usage over multiple years, balance of funds, compliance with regulatory requirements, changes in investment projects, and detailed tables of fund usage and project progress. The document references regulatory guidelines related to the management of raised funds and includes financial figures and project status updates. It is not a general annual or quarterly report, nor is it an earnings release or a call transcript. It is not a simple announcement or a certification but a comprehensive report focused on the use of capital raised by the company. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including the use of raised funds. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2024-08-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.